IP Library Granted Patent US 6,890,716
Granted Patent B1
US 6,890,716 · App. 09/674,876 · Granted May 10, 2005

Recombinant cell line and screening method for identifying agents which regulate apoptosis and tumor suppression

Assignee: Howard Hughes Medical Institute
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,890,716
App. No.
09/674,876
Granted
May 10, 2005
Kind
B1
Abstract

This invention provides recombinant cell lines and screening methods useful for identifying agents that induce apoptosis in target cells and therefore may be used to advantage in the treatment of neoplastic disorders.

Claims (12)

1. A recombinant cell line for assessing therapeutic agents that regulate apoptosis, said recombinant cell line being stably transfected with:

a) a first plasmid expressing a p300/CBP responsive promoter operably linked to a first reporter gene;

b) a second plasmid expressing a non p300/CBP responsive promoter operably linked to a second reporter gene; and optionally

c) a third plasmid expressing a selectable marker gene.

2. The cell line of claim 1 , said cell line being further stably transfected with an additional plasmid encoding wild-type p300/CBP to augment endogenously expressed p300/CBP protein levels.

3. A screening method for determining if a therapeutic agent inhibits p300/CBP activity thereby inducing apoptosis, comprising:

a) contacting recombinant cells with said therapeutic agent, said recombinant cells being stably transfected with:

i) a first plasmid expressing a p30/CBP responsive promoter operably linked to a first reporter gene;

ii) a second plasmid expressing a, non p300/CBP responsive promoter operably linked to a second reporter gene; and optionally

iii) a third plasmid expressing a selectable marker gene;

b) assessing said recombinant cells for repression of the first reporter gene by said therapeutic agent; and

c) assessing said recombinant cells for repression of the second reporter gene by said therapeutic agent, repression in step b) and not step c) indicating that the therapeutic agent inhibits p300/CBP activity and thereby induces apoptosis.

Assignments (2)
CONFIRMATORY LICENSE Recorded Aug 2, 2021
From: RUTGERS, THE STATE UNIV OF NJ
To: NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR
Reel/Frame 057057/0307 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 12, 2002
From: WHITE, EILEEN P.
To: HOWARD HUGHES MEDICAL INSTITUTE
Reel/Frame 013178/0802 →
Continuity (4)
Provisional Application 6010768900 · Nov 9, 1998
Provisional Application 6009287100 · Jul 15, 1998
Provisional Application 6009139100 · Jul 1, 1998
Provisional Application 6008466400 · May 7, 1998